Sitagliptin Beats Pioglitazone for Stringent HbA1c Targets in Triple Therapy
This target trial emulation gives Endocrinology and Obesity pharmacists comparative real-world data on adding sitagliptin versus pioglitazone to metformin plus sulfonylurea, favoring sitagliptin on weight, lipids, and stringent glycemic goal attainment.
Sitagliptin outperforms pioglitazone in metabolic outcomes for T2DM.
This study provides insights into the comparative effectiveness of sitagliptin and pioglitazone as additions to metformin and sulfonylurea in managing type 2 diabetes mellitus (T2DM). Sitagliptin led to a higher probability of achieving intensive glycemic control (HbA1c < 6.5%) and showed greater reductions in body weight and low-density lipoprotein (LDL) cholesterol compared to pioglitazone. The findings suggest sitagliptin may offer a more favorable metabolic profile and better glycemic targets in patients with T2DM, influencing drug selection in practice. Sitagliptin may be preferred over pioglitazone for better metabolic outcomes in T2DM patients on metformin and sulfonylurea.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Kim TH, Hwang Y, Woo S, Lee K, Son Y, Park S, Kim H, Shin JY, Cho Y, Shin D, Cho D, Lee KJ, Kim CH, Rhee SY, Yon DK
Citation:Kim TH, Hwang Y, Woo S, et al. Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes: An emulated target trial. Medicine. 2026;105(34):e50241. doi:10.1097/MD.0000000000050241
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.